Literature DB >> 10837430

Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing ampC.

N Caroff1, E Espaze, D Gautreau, H Richet, A Reynaud.   

Abstract

Escherichia coli usually produces only very small amounts of a constitutive AmpC beta-lactamase, but clinical strains overproducing this enzyme have been isolated. Three different ampC promoters of E. coli clinical strains were cloned upstream of the chloramphenicol acetyltransferase (CAT) gene in the pKK232-8 reporter plasmid and their relative strengths were compared by two different methods. The strength of the promoters from AmpC hyperproducers was 70- to 120-fold higher than those from a low-level AmpC producer. One of the strong promoters, which differs from strain K12 at bases -88, -82, -42, -18, -1 and +58, was mutated to abolish the -42 mutation. This change resulted in a 43-fold decrease in CAT concentration. In another promoter, with eight different mutations at positions -88, -82, -32, -18, -1, +5, +24 and +58, the -32T-->A transversion, which created perfect homology with the -35 consensus sequence, was reverted; this led to a 13-fold decrease in CAT concentration. The -42 and -32 mutations play an important role in E. coli resistance to beta-lactams by increasing ampC transcription.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837430     DOI: 10.1093/jac/45.6.783

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  54 in total

Review 1.  Plasmid-determined AmpC-type beta-lactamases.

Authors:  Alain Philippon; Guillaume Arlet; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Practical approach for reliable detection of AmpC beta-lactamase-producing Enterobacteriaceae.

Authors:  Silke Polsfuss; Guido V Bloemberg; Jacqueline Giger; Vera Meyer; Erik C Böttger; Michael Hombach
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

3.  High-level expression of ampC beta-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extended-spectrum-cephalosporin treatment.

Authors:  L K Siu; Po-Liang Lu; J-Y Chen; F M Lin; Shan-Chwen Chang
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

4.  -11 Mutation in the ampC promoter increasing resistance to beta-lactams in a clinical Escherichia coli strain.

Authors:  S Corvec; N Caroff; E Espaze; J Marraillac; A Reynaud
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

5.  Evaluation of four phenotypic methods to detect plasmid-mediated AmpC β-lactamases in clinical isolates.

Authors:  M J Gude; C Seral; Y Sáenz; M González-Domínguez; C Torres; F J Castillo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-26       Impact factor: 3.267

6.  Monitoring and characterization of extended-spectrum beta-lactamases in Escherichia coli strains from healthy and sick animals in Spain in 2003.

Authors:  Laura Briñas; Miguel Angel Moreno; Tirushet Teshager; Yolanda Sáenz; María Concepción Porrero; Lucas Domínguez; Carmen Torres
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

7.  Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates.

Authors:  Teresa Spanu; Maurizio Sanguinetti; Mario Tumbarello; Tiziana D'Inzeo; Barbara Fiori; Brunella Posteraro; Rosaria Santangelo; Roberto Cauda; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

8.  Beta-lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals.

Authors:  Laura Briñas; Myriam Zarazaga; Yolanda Sáenz; Fernanda Ruiz-Larrea; Carmen Torres
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Prevalence of extended-spectrum β-lactamase-producing Escherichia coli on Bavarian dairy and beef cattle farms.

Authors:  A Schmid; S Hörmansdorfer; U Messelhäusser; A Käsbohrer; C Sauter-Louis; R Mansfeld
Journal:  Appl Environ Microbiol       Date:  2013-03-01       Impact factor: 4.792

10.  AmpC beta-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins.

Authors:  Hedi Mammeri; Hasan Nazic; Thierry Naas; Laurent Poirel; Sophie Léotard; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.